Saturation of acyl chains converts cardiolipin from an antagonist to an activator of Toll-like receptor-4.
Animals
Anti-Infective Agents
/ chemistry
Binding, Competitive
Cardiolipins
/ chemistry
Cell Survival
/ drug effects
Chemokine CXCL10
/ metabolism
HEK293 Cells
Humans
Lipopolysaccharide Receptors
/ metabolism
Lipopolysaccharides
/ metabolism
Lymphocyte Antigen 96
/ genetics
Macrophages
/ cytology
Mice
Monocytes
/ cytology
NF-kappa B
/ metabolism
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Protein Binding
Signal Transduction
/ drug effects
Toll-Like Receptor 4
/ agonists
Tumor Necrosis Factor-alpha
/ metabolism
Anti-inflammatory
Barth syndrome
Cardiolipin
Inflammation resolution
TLR4-agonist
TLR4-antagonist
Toll-like receptor (TLR)
Vaccine adjuvant
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
15
02
2019
accepted:
23
04
2019
revised:
12
04
2019
pubmed:
8
5
2019
medline:
28
8
2019
entrez:
8
5
2019
Statut:
ppublish
Résumé
Cardiolipins (CLs) are tetra-acylated diphosphatidylglycerols found in bacteria, yeast, plants, and animals. In healthy mammals, CLs are unsaturated, whereas saturated CLs are found in blood cells from Barth syndrome patients and in some Gram-positive bacteria. Here, we show that unsaturated but not saturated CLs block LPS-induced NF-κB activation, TNF-α and IP-10 secretion in human and murine macrophages, as well as LPS-induced TNF-α and IL-1β release in human blood mononuclear cells. Using HEK293 cells transfected with Toll-like receptor 4 (TLR4) and its co-receptor Myeloid Differentiation 2 (MD2), we demonstrate that unsaturated CLs compete with LPS for binding TLR4/MD2 preventing its activation, whereas saturated CLs are TLR4/MD2 agonists. As a consequence, saturated CLs induce a pro-inflammatory response in macrophages characterized by TNF-α and IP-10 secretion, and activate the alternative NLRP3 inflammasome pathway in human blood-derived monocytes. Thus, we identify that double bonds discriminate between anti- and pro-inflammatory properties of tetra-acylated molecules, providing a rationale for the development of TLR4 activators and inhibitors for use as vaccine adjuvants or in the treatment of TLR4-related diseases.
Identifiants
pubmed: 31062071
doi: 10.1007/s00018-019-03113-5
pii: 10.1007/s00018-019-03113-5
pmc: PMC6697720
doi:
Substances chimiques
Anti-Infective Agents
0
CXCL10 protein, human
0
Cardiolipins
0
Chemokine CXCL10
0
Lipopolysaccharide Receptors
0
Lipopolysaccharides
0
Lymphocyte Antigen 96
0
NF-kappa B
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Toll-Like Receptor 4
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3667-3678Subventions
Organisme : Wellcome Trust
ID : WT100321/z/12/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : RG87390
Pays : United Kingdom
Organisme : Fondation Philippe Wiener - Maurice Anspach
ID : N/A
Organisme : H2020 Marie Skłodowska-Curie Actions
ID : TLR4-CAT PIEF-GA-2012-326481
Organisme : Medical Research Council
ID : MR/S002340/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108045/Z/15/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : European Research Council
ID : ERC-2013-CoG 614578
Pays : International
Organisme : Medical Research Council
ID : MR/P02260X/1
Pays : United Kingdom
Organisme : Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture
ID : F3/5/5-MCF/XH/FC-17514
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/H003916/1
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Références
Dig Dis Sci. 1999 Apr;44(4):852-6
pubmed: 10219848
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1743-8
pubmed: 10677528
Clin Chem. 2002 Sep;48(9):1390-7
pubmed: 12194913
Microbes Infect. 2002 Jul;4(8):837-51
pubmed: 12270731
Pharmacol Rev. 1957 Jun;9(2):242-6
pubmed: 13465304
J Immunol. 2005 Jan 15;174(2):1091-6
pubmed: 15634934
Inflamm Bowel Dis. 2005 Jun;11(6):567-75
pubmed: 15905704
FEBS Lett. 2006 Oct 9;580(23):5450-5
pubmed: 16973164
J Immunol. 2006 Nov 15;177(10):6880-8
pubmed: 17082602
Cell. 2007 Sep 7;130(5):906-17
pubmed: 17803912
Clin Chem. 2008 Feb;54(2):371-8
pubmed: 18070816
J Immunol. 2008 Jul 15;181(2):1245-54
pubmed: 18606678
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4
pubmed: 18835160
Curr Opin Hematol. 2009 Jan;16(1):14-9
pubmed: 19057200
Anal Biochem. 2009 Apr 15;387(2):230-7
pubmed: 19454236
Pharmacol Rev. 2009 Jun;61(2):177-97
pubmed: 19474110
Comp Immunol Microbiol Infect Dis. 2010 Sep;33(5):443-54
pubmed: 19732955
Nat Rev Microbiol. 2010 Jan;8(1):8-14
pubmed: 19946286
J Biol Chem. 2010 Mar 19;285(12):8695-702
pubmed: 20018893
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Lupus. 2010 Apr;19(4):347-53
pubmed: 20353968
Cell Mol Life Sci. 2010 Dec;67(24):4109-34
pubmed: 20680392
J Biol Chem. 2011 Mar 18;286(11):9587-97
pubmed: 21228274
Biotechnol Adv. 2012 Jan-Feb;30(1):251-60
pubmed: 21664961
Proc Natl Acad Sci U S A. 2012 May 8;109(19):7421-6
pubmed: 22532668
J Inflamm (Lond). 2012 Jun 21;9(1):25
pubmed: 22721508
Adv Protein Chem Struct Biol. 2012;88:69-132
pubmed: 22814707
Biochim Biophys Acta. 2013 Mar;1831(3):582-8
pubmed: 23200781
Br J Haematol. 2014 Jan;164(2):165-76
pubmed: 24180619
J Med Chem. 2014 May 8;57(9):3612-22
pubmed: 24188011
Chem Phys Lipids. 2014 Apr;179:42-8
pubmed: 24220496
Prog Lipid Res. 2014 Jul;55:1-16
pubmed: 24769127
Nat Rev Immunol. 2014 Aug;14(8):546-58
pubmed: 25060580
Cold Spring Harb Perspect Biol. 2014 Nov 13;7(3):a016253
pubmed: 25395297
Nat Med. 2015 Mar;21(3):248-55
pubmed: 25686105
Cell Mol Life Sci. 2015 Oct;72(20):3971-82
pubmed: 25956320
Nat Med. 2015 Jul;21(7):677-87
pubmed: 26121197
J Intern Med. 2015 Oct;278(4):369-95
pubmed: 26212387
Sci Signal. 2015 Sep 22;8(395):ra95
pubmed: 26396268
Immunity. 2016 Apr 19;44(4):833-46
pubmed: 27037191
J Lipid Res. 2016 Jul;57(7):1308-21
pubmed: 27179363
Appl Environ Microbiol. 2016 Jun 30;82(14):4264-78
pubmed: 27208127
Clin Transl Immunology. 2016 May 20;5(5):e85
pubmed: 27350884
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Jan;1862(1):8-24
pubmed: 27498292
J Control Release. 2017 Feb 10;247:182-193
pubmed: 28040465
Lipids. 2017 Feb;52(2):99-108
pubmed: 28070695
Nat Commun. 2017 Jan 11;8:13944
pubmed: 28074841
Front Immunol. 2017 Jan 27;8:43
pubmed: 28191008
Nat Rev Immunol. 2017 Jun;17(6):363-375
pubmed: 28393922
Int J Mol Sci. 2017 Nov 03;18(11):null
pubmed: 29099761
Cell Mol Life Sci. 2018 Jul;75(13):2431-2446
pubmed: 29313060
Elife. 2018 Jan 24;7:
pubmed: 29368691
PLoS One. 2018 Mar 14;13(3):e0193601
pubmed: 29538403
J Immunol. 2018 May 1;200(9):3047-3052
pubmed: 29602772
Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):4158-4163
pubmed: 29618609
Immunopharmacology. 1995 Apr;29(3):187-205
pubmed: 7542643
Ryumachi. 1994 Dec;34(6):961-6
pubmed: 7863386
Infect Immun. 1995 Mar;63(3):833-9
pubmed: 7868254
Eur J Biochem. 1993 Mar 15;212(3):727-35
pubmed: 8385010
Br J Pharmacol. 1993 Aug;109(4):1110-9
pubmed: 8401922
J Leukoc Biol. 1996 Feb;59(2):241-7
pubmed: 8603996
Int J Biochem Cell Biol. 1996 Jan;28(1):43-51
pubmed: 8624843